Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer"
- PMID: 32715579
- PMCID: PMC7648346
- DOI: 10.1634/theoncologist.2020-0385
Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer"
Comment in
-
In Reply.Oncologist. 2020 Nov;25(11):e1819. doi: 10.1002/onco.13538. Epub 2020 Oct 3. Oncologist. 2020. PMID: 32969114 Free PMC article.
Comment on
-
HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer.Oncologist. 2020 Oct;25(10):886-893. doi: 10.1634/theoncologist.2019-0922. Epub 2020 May 11. Oncologist. 2020. PMID: 32353192 Free PMC article.
References
-
- Primrose JN, Fox R, Palmer DH et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol 2017;35(suppl 15):4006a.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials